Lead Product(s): Centyrins
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Ionis Pharmaceuticals
Deal Size: $1,400.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2020
As per the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.